|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar
|
|
3
|
Kawanami T, Takiguchi S, Ikeda N and
Funakoshi A: A humanized anti-IGF-1R monoclonal antibody (R1507)
and/or metformin. Oncol Rep. 27:867–872. 2012.PubMed/NCBI
|
|
4
|
Kasuya K, Tsuchida A, Nagakawa Y, et al:
Hypoxia-inducible factor-1alpha expression and gemcitabine
chemotherapy. Oncol Rep. 26:1399–1406. 2011.PubMed/NCBI
|
|
5
|
Chen H, Wei W, Guo Y, et al: Enhanced
effect of gemcitabine by emodin against pancreatic cancer in vivo
via cytochrome C-regulated apoptosis. Oncol Rep. 25:1253–1261.
2011.PubMed/NCBI
|
|
6
|
Di Marco M, Di Cicilia R, Macchini M, et
al: Metastatic pancreatic cancer: Is gemcitabine still the best
standard treatment? (Review). Oncol Rep. 23:1183–1192.
2010.PubMed/NCBI
|
|
7
|
Burris HA 3rd, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
8
|
Neoptolemos JP, Stocken DD, Bassi C, et
al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs
gemcitabine following pancreatic cancer resection: a randomized
controlled trial. Jama. 304:1073–1081. 2010. View Article : Google Scholar
|
|
9
|
Banerjee D, Mayer-Kuckuk P, Capiaux G,
Budak-Alpdogan T, Gorlick R and Bertino JR: Novel aspects of
resistance to drugs targeted to dihydrofolate reductase and
thymidylate synthase. Biochim Biophys Acta. 1587:164–173. 2002.
View Article : Google Scholar
|
|
10
|
Muerkoster S, Wegehenkel K, Arlt A, et al:
Tumor stroma interactions induce chemoresistance in pancreatic
ductal carcinoma cells involving increased secretion and paracrine
effects of nitric oxide and interleukin-1beta. Cancer Res.
64:1331–1337. 2004. View Article : Google Scholar
|
|
11
|
Yamauchi K, Yang M, Hayashi K, et al:
Induction of cancer metastasis by cyclophosphamide pretreatment of
host mice: an opposite effect of chemotherapy. Cancer Res.
68:516–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu YJ, Muldoon LL, Dickey DT, Lewin SJ,
Varallyay CG and Neuwelt EA: Cyclophosphamide enhances human tumor
growth in nude rat xenografted tumor models. Neoplasia. 11:187–195.
2009.PubMed/NCBI
|
|
13
|
Liu QH, Zhang J, Zhao CY, et al: Surviving
cells after treatment with gemcitabine or 5-fluorouracil for the
study of de novo resistance of pancreatic cancer. Cancer Lett.
314:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mosser DD and Morimoto RI: Molecular
chaperones and the stress of oncogenesis. Oncogene. 23:2907–2918.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garrido C, Brunet M, Didelot C, Zermati Y,
Schmitt E and Kroemer G: Heat shock proteins 27 and 70:
anti-apoptotic proteins with tumorigenic properties. Cell Cycle.
5:2592–2601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao L, Liu L, Wang S, Zhang YF, Yu L and
Ding YQ: Differential proteomic analysis of human colorectal
carcinoma cell lines metastasis-associated proteins. J Cancer Res
Clin Oncol. 133:771–782. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang SH, Kang KW, Kim KH, et al:
Upregulated HSP27 in human breast cancer cells reduces Herceptin
susceptibility by increasing Her2 protein stability. BMC Cancer.
8:2862008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Larkin SE, Holmes S, Cree IA, et al:
Identification of markers of prostate cancer progression using
candidate gene expression. Br J Cancer. 106:157–165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xia Y, Liu Y, Wan J, et al: Novel triazole
ribonucleoside down-regulates heat shock protein 27 and induces
potent anticancer activity on drug-resistant pancreatic cancer. J
Med Chem. 52:6083–6096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ciocca DR and Calderwood SK: Heat shock
proteins in cancer: diagnostic, prognostic, predictive, and
treatment implications. Cell Stress Chaperones. 10:86–103. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Soti C, Nagy E, Giricz Z, Vigh L, Csermely
P and Ferdinandy P: Heat shock proteins as emerging therapeutic
targets. Br J Pharmacol. 146:769–780. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schafer C, Seeliger H, Bader DC, et al:
Heat shock protein 27 as a prognostic and predictive biomarker in
pancreatic ductal adenocarcinoma. J Cell Mol Med. View Article : Google Scholar : 2011.PubMed/NCBI
|
|
23
|
Berrieman HK, Cawkwell L, O'Kane SL, Smith
L and Lind MJ: Hsp27 may allow prediction of the response to
single-agent vinorelbine chemotherapy in non-small cell lung
cancer. Oncol Rep. 15:283–286. 2006.PubMed/NCBI
|
|
24
|
Yang YX, Xiao ZQ, Chen ZC, et al: Proteome
analysis of multidrug resistance in vincristine-resistant human
gastric cancer cell line SGC7901/VCR. Proteomics. 6:2009–2021.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liao WC, Wu MS, Wang HP, Tien YW and Lin
JT: Serum heat shock protein 27 is increased in chronic
pancreatitis and pancreatic carcinoma. Pancreas. 38:422–426. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leonardi R, Pannone G, Magro G, Kudo Y,
Takata T and Lo Muzio L: Differential expression of heat shock
protein 27 in normal oral mucosa, oral epithelial dysplasia and
squamous cell carcinoma. Oncol Rep. 9:261–266. 2002.PubMed/NCBI
|
|
27
|
Vargas-Roig LM, Gago FE, Tello O, Aznar JC
and Ciocca DR: Heat shock protein expression and drug resistance in
breast cancer patients treated with induction chemotherapy. Int J
Cancer. 79:468–475. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et
al: Proteomics finding heat shock protein 27 as a biomarker for
resistance of pancreatic cancer cells to gemcitabine. Int J Oncol.
31:1345–1350. 2007.PubMed/NCBI
|
|
29
|
Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et
al: A proteomic profiling of gemcitabine resistance in pancreatic
cancer cell lines. Mol Med Report. 1:429–434. 2008.PubMed/NCBI
|
|
30
|
Heinrich JC, Tuukkanen A, Schroeder M,
Fahrig T and Fahrig R: RP101 (brivudine) binds to heat shock
protein HSP27 (HSPB1) and enhances survival in animals and
pancreatic cancer patients. J Cancer Res Clin Oncol. 137:1349–1361.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arrigo AP: Hsp27: novel regulator of
intracellular redox state. IUBMB Life. 52:303–307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakashima M, Adachi S, Yasuda I, et al:
Phosphorylation status of heat shock protein 27 plays a key role in
gemcitabine-induced apoptosis of pancreatic cancer cells. Cancer
Lett. 313:218–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Taba K, Kuramitsu Y, Ryozawa S, et al:
Heat-shock protein 27 is phosphorylated in gemcitabine-resistant
pancreatic cancer cells. Anticancer Res. 30:2539–2543.
2010.PubMed/NCBI
|
|
34
|
Baylot V, Andrieu C, Katsogiannou M, et
al: OGX-427 inhibits tumor progression and enhances gemcitabine
chemotherapy in pancreatic cancer. Cell Death Dis. 2:e2212011.
View Article : Google Scholar : PubMed/NCBI
|
